Compound Libraries. United States. Europe. Toll Free: Fax:

Size: px

Start display at page:

Download "Compound Libraries. United States. Europe. Toll Free: Fax:"

James Greer
6 years ago
Views:

1 Inhibitor United tates Toll Free: Fax: Europe Compound Libraries Tel: Fax: Inhibitor

2 ince Jan of 2013: elleck products have been cited in 105 studies from cience, ature and Cell. ature, 2018, 553(7686): ature, 2018, 553(7686): ature, 2018, 553(7686): ature, 2017, 549(7673): ature, 2017, 549(7673): ature, 2017, 551(7679): ature, 2017, 550(7675): ature, 2017, 550(7676): ature, 2017, 552(7683): ature, 2017, 550(7677): ature, 2017, 552(7683): ature, 2017, 551(7678): ature, 2017, 551(7682): ature, 2017, 550(7674): ature, 2017, 550(7676): ature, 2017, 548(7668): ature, 2017, 549(7672): ature, 2017, 548(7669): ature, 2017, 548(7668): ature, 2017, 548(7667): ature, 2017, 170(5): ature, 2017, 546(7658): ature, 2017, 546(7658): ature, 2017, 545(7654): ature, 2017, 543(7647): ature, 2017, 541(7638): ature, 2017, 542(7641): ature, 2016, 539(7627): ature, 2016, 540(7631): ature, 2016, 539(7629): ature, 2016, 539(7628): ature, 2016, 538(7626): ature, 2016, 535(7613): ature, 2016, 537(7620): ature, 2016, 530(7590): ature, 2016, 534(7607): ature, 2016, 32(7597): ature, 2016, 531(7596): ature, 2015, 528(7582): ature, 2015, 522(7557): ature, 2015, 527(7576): ature, 2015, 522(7556): ature, 2015, 521(7552): ature, 2015, 521(7553): ature, 2015, 520(7549): ature, 2015, 518(7538): ature, 2015, 517(7534): ature, 2015, 522(7555): ature, 2015, 517(7535): ature, 2015, 523(7558):92-5. ature, 2015, 521(7552): ature, 2015, 520(7547): ature, 2015, 524(7566): ature, 2015, 517(7536): ature, 2015, 519(7543): ature, 2014, 511(7507):90-3. ature, 2014, 510(7504): ature, 2014, 509(7498): ature, 2014, 508(7494): ature, 2013, 501(7466): ature, 2013, 500(7461): ature, 2013, 498(7452): ature, 2013, 496(7446): ature, 2013, 493(7430):51-5. cience, 2017, 358(6367). cience, 2017, 356(6336). cience, 2017, 355(6320): cience, 2017, 355(6320): cience, 2016, 354(6315). cience, 2016, 351(6277):aad3680. cience, 2016, 352(6283): cience, 2016, 352(6282): cience, 2016, 353(6302): cience, 2013, 341(6146): cience, 2013, 339(6120): Cell, 2018, 172(3): Cell, 2018, 172(3): Cell, 2018, 172(3): Cell, 2018, 172(1-2): Cell, 2017, 171(4): Cell, 2017, 171(3): Cell, 2017, 161(4): Cell, 2017, 171(1): Cell, 2017, 171(3): Cell, 2017, 171(7): Cell, 2017, 171(7): Cell, 2017, 171(5): Cell, 2017, 170(5): Cell, 2017, 170(3): Cell, 2017, 170(5): Cell, 2017, 170(3): Cell, 2017, 169(2): Cell, 2017, 169(2): Cell, 2017, 168(5): Cell, 2017, 168(1-2): Cell, 2016, 167(1): Cell, 2016, 167(7): Cell, 2016, 164(1-2): Cell, 2016, 165(1): Cell, 2015, 162(2): Cell, 2015, 160(1-2): Cell, 2014, 159(5): Cell, 2014, 158(5): Cell, 2013, 154(5): Cell, 2013, 153(4):

Q1 Why select elleck Libraries? Publish papers fast!

aving you Q2 ot sure how to use a library?

help! time, compared to other methods, with article impacts

A quick and easy way to get your article published.

2y ature Materials 39.74 UCF JR Chan 1y8m ature Medicine 29.

12 Baylor College of Medicine XH Zhang 1y10m ature

12 Lund University JU Kazi 2y8m Cancer Letters 6.

6 Tsinghua University GF Xiao 1y11m Journal of Virology 4.

3 Q1 Why select elleck Libraries? Publish papers fast! Average publish time with selleck libraries is only two years! aving you Q2 ot sure how to use a library? elleck provides free technical advice and experiment design help! time, compared to other methods, with article impacts ranging from A quick and easy way to get your article published. Institute Group Duration Journal IF Tsinghua University Y Du 2y ature Materials UCF JR Chan 1y8m ature Medicine Roche Innovation Center Basel CA Cowan 2y4m ature Cell Biology BC Cancer Agency Dedhar 3y ature Communications Baylor College of Medicine XH Zhang 1y10m ature Communications Lund University JU Kazi 2y8m Cancer Letters 6.34 University of Wisconsin X Zhao 1y6m tem Cells 5.6 Tsinghua University GF Xiao 1y11m Journal of Virology 4.66 University of Bergen BT Gjertsen 1y7m Pharmacological Research 4.48 University of evada B Ferguson 1y Molecular utrition & Food Research 4.48 Moffitt Cancer Center E chönbrunn 3y ChemMedChem Average 2 years Q3 o time? elleck s partners can provide a platform for your screening needs:

Disease research applications of compound libraries tem cell study applications of compound libraries Author bought elleck s FDA Library in eptember of 2015.

66) in August of 2017, creening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection, PMID: 28814523 In eptember of 2012, the authors purchased

Article published in the January of 2015 issue of ature Cell Biology (IF:20.06), White-to-brown metabolic conversion of human adipocytes by JAK inhibition, PMID: 25487280.

Japanese encephalitis is caused by the Japanese encephalitis virus (JEV), the usage of vaccines has decreased the rates of morbidity and mortality from infections, but,

Experiment Design Background: Differentiation/transdifferentiation is a new approach to treating certain diseases.

becomes the new treatment of obesity. 1. High-throughput drug screening 2. Phenotype research Experiment design 1. High-throughput drug screening 2. Phenotype verification 1.

Time-effect relationship verification Compound Librarie: elleck FDA-approved Drug Library Model: JEV infectious clone with luciferase reporter Indicators: inhibition> 90%,

4 Disease research applications of compound libraries tem cell study applications of compound libraries Author bought elleck s FDA Library in eptember of The article was published in the Journal of Virology (IF:4.66) in August of 2017, creening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection, PMID: In eptember of 2012, the authors purchased elleck Epigenetics Compound Library, tem Cell ignaling Compound Library and GPCR Compound Library. Article published in the January of 2015 issue of ature Cell Biology (IF:20.06), White-to-brown metabolic conversion of human adipocytes by JAK inhibition, PMID: Background: A certain disease, which, lacks any form of treatment. Japanese encephalitis is caused by the Japanese encephalitis virus (JEV), the usage of vaccines has decreased the rates of morbidity and mortality from infections, but, there is still no targeted cure or treatment for patients suffering from symptoms. Experiment Design Background: Differentiation/transdifferentiation is a new approach to treating certain diseases. besity increases risk of diabetes and cardiovascular disease, the conversion of white adipocytes into brown adipocytes can effectively suppress obesity, conversion method becomes the new treatment of obesity. 1. High-throughput drug screening 2. Phenotype research Experiment design 1. High-throughput drug screening 2. Phenotype verification 1. Dose-effect relationship verification 2. Time-effect relationship verification Compound Librarie: elleck FDA-approved Drug Library Model: JEV infectious clone with luciferase reporter Indicators: inhibition> 90%, viability> 80%, dose response relationship establishment, five hit drugs were confirmed, of which three were calcium channel inhibitors 3. Antiviral spectrum study Compound Librarie: elleck Epigenetics Compound Library, tem Cell ignaling Compound Library, GPCR Compound Library Model: PPARG2-MPC Index: The expression of UCP1 and FABP4, two compounds named Tofacitinib and R406 were selected 1. Transcription, expression profiling 2. Validation at cell and tissue level 3. Mechanism study 4. in vivo efficacy verification 3. Mechanism research 4. Further mechanism research 1. Using other calcium channel inhibitors can have similar effects 2. Identify the drug s target site for JEV The JAK/TAT signaling pathway is vital in the transformation of brown adipocytes

5 Bioactive Compound Library Cat.o. L1700 We carry 3341 (data obtained in March 2018 and updated every three months) bioactive chemical compounds for high throughput screening (HT) and high content screening (HC) Bioactivity and safety confirmed by preclinical research and clinical trials ome compounds have been approved by the FDA MR and HPLC validated to ensure high purity ize (Pre-dissolved in DM) FDA-approved Drug Library Cat.o. L1300 A unique collection of 1508 (data obtained in March 2018 and updated every three months) FDA approved drugs for high throughput screening (HT) and high content screening (HC) Locate new targets for old drugs Bioactivity and safety confirmed by clinical trials All compounds have been approved by FDA Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc tructurally diverse, medicinally active, and cell permeable ize (Pre-dissolved in DM) DM solution) DM solution) umber of Bioactive Adrenergic Receptor DA/RA ynthesis AChR 5-HT Receptor CX Histamine Receptor Estrogen/progestogen Receptor Calcium Channel PI3K HDAC Histone Methyltransferase CDK odium Channel Dopamine Receptor Immunology & Inflammation related P450 (e.g. CYP17) Dehydrogenase Topoisomerase EGFR Glucocorticoid Receptor Epigenetic Reader Domain RAA PDE PARP JAK Microtubule Associated HP (e.g. HP90) Reverse Transcriptase TGF-beta/mad mtr GABA Receptor Potassium Channel Vitamin PPAR GK-3 MEK Wnt/beta-catenin Akt Rho Raf Aurora Kinase irtuin IκB/IKK Androgen Receptor TAT p38 MAPK VEGFR phosphatase Caspase R ATPase F-κB pioid Receptor Cysteine Protease Carbonic Anhydrase ther Targets umber of FDA-approved Adrenergic Receptor AChR CX 5-HT Receptor DA/RA ynthesis Histamine Receptor Estrogen/progestogen Receptor odium Channel Calcium Channel Dopamine Receptor Glucocorticoid Receptor RAA Topoisomerase P450 (e.g. CYP17) PDE Potassium Channel Vitamin GABA Receptor HDAC Microtubule Associated PPAR Carbonic Anhydrase Dehydrogenase DPP-4 EGFR JAK Reverse Transcriptase Immunology & Inflammation related Journals Citing of this Library HMG-CoA Reductase pioid Receptor CDK HCV Protease PARP Proton Pump Retinoid Receptor Androgen Receptor HIV Protease MA P2 Receptor Thrombin Aromatase Autophagy c-kit,pdgfr,vegfr DHFR DA alkylator EGFR,HER2 MEK MMP PI3K erine Protease Akt Endothelin Receptor phosphatase R 1P Receptor ther Targets at Med, 2017,23(4): Pancreas,2015,44(1):152-7 Drug Discov Today,2017,22(2): Int J Mass pectrom,2015,377: Journals Citing of this Library Antimicrob Agents Chemother,2016,60(11): at Prod Rep,2014,31(6): PLo ne,2015,10(6):e in Exp Metastasis,2016,33(4): at Med,2017,23(4): Pharmacol Res,2016,113(Pt A): Mol Cancer Ther,2015,14(5): ci Rep,2016,6:33427 PLo ne,2016,11(2):e at Med,2014,20(8): Transl ncol,2017,10(4): ensors (Basel),2016,16(3) in Cancer Res,2015,21(5): J Biomol creen,2015,20(9): PLo ne,2015,10(11):e ncotarget,2015,6(3): ncotarget,2014,5(15): Head eck,2015,37(12): Biosens Bioelectron,2015,68: Curr Protoc Chem Biol,2014,4: Cell Cycle,2015,14(1): Mol Cancer Res,2014,12(5): Cell Death Dis,2017,8(6):e2904 Antimicrob Agents Chemother,2015,60(2): in Cancer Res,2016, / Drug Discov Today,2017,22(2): Antimicrob Agents Chemother,2014,58(8): Cancer Res,2014,74:1702 Antiviral Res,2016,135:81-90 Antiviral Res,2017,146:76-85 ci Rep,2017,7(1):525 PLo ne,2015,10(11):e Cell Death Discov,2016,2:16041 Pharmacol Res,2016,113(Pt A): Mol Cancer Ther,2015,14(5): ncotarget,2014,5(15): PLo ne,2016,11(2):e at Med,2014,20(8): Biosens Bioelectron,2015,68: ensors (Basel),2016,16(3) in Cancer Res,2015,21(5): Cell Cycle,2015,14(1): Biochem Biophys Res Commun,2014,452(3): PLo ne,2015,10(11):e PLo egl Trop Dis,2016,10(4):e ncotarget,2015,6(3): PLo ne,2014,9(6):e99440 Mol Cancer Res,2014,12(5): MedChemComm,2013,4, Head eck,2015,37(12): Mol Cell Endocrinol,2017, (17) Curr Protoc Chem Biol,2014,4:

6 Kinase Inhibitor Library Cat.o. L1200 A unique collection of 585 (data obtained in March 2018 and updated every three months) kinase inhibitors for high throughput screening (HT) and high content screening (HC) Bioactivity and safety confirmed by preclinical research and clinical trials ome inhibitors have been approved by the FDA Targets kinases such as RTKs, PI3K, Aurora Kinase, CDK, and MEK Most are ATP competitive tructurally diverse, medicinally active, and cell permeable atural Product Library Cat.o. L1400 A unique collection of 775 (data obtained in March 2018 and updated every three months) natural products for high throughput screening (HT) and high content screening (HC) tructurally diverse, bioactive, and cell permeable ize (Pre-dissolved in DM) ize (Pre-dissolved in DM) DM solution) DM solution) Journals Citing of this Library 35 at Med,2017,23(4): Mol Cancer Ther,2015,14(5): Biochem Biophys Res Commun,2016,473(4): PLo ne,2016,11(2):e at Med,2014,20(8): Biosens Bioelectron,2015,68: umber of Kinase Inhibitors PI3K CDK EGFR JAK MEK GK-3 mtr Akt Aurora Kinase p38 MAPK Raf c-met VEGFR thers AMPK BTK RCK ATM/ATR c-kit,pdgfr,vegfr EGFR,HER2 FGFR IGF-1R PLK ALK Bcr-Abl Chk FAK IκB/IKK PKC rc yk ERK JK LRRK2 mtr,pi3k Pim FLT3 HER2 PAK 6 Kinase Trk receptor CaMK c-met,vegfr FGFR,VEGFR PDGFR PDK ACK ATM/ATR,mTR Autophagy,mTR Autophagy,PI3K Autophagy,RCK EGFR,JAK 1P Receptor FGFR,PDGFR,VEGFR Rho Akt,CDK,PKA ther Targets Mol utr Food Res,2016, /mnfr PeerJ,2017,5:e3283 ensors (Basel),2016,16(3) Mol utr Food Res,2017,61(4) Cytotechnology,2016,68(4): PLo ne,2015,10(11):e PLo egl Trop Dis,2015,9(6):e Pharmacol Res,2016,113(Pt A): Curr Protoc Chem Biol,2014,4: in Cancer Res,2015,21(5): Cell Cycle,2015,14(1): ncotarget,2015,6(3): Mol Cancer Res,2014,12(5): ncotarget,2014,5(15): Head eck,2015,37(12): Journals Citing of this Library at Med,2017,23(4): Cancer Lett,2017,405:73-78 Biochim Biophys Acta,2017,1861(4): at Commun,2017,8:15289 Mol Cancer Ther,2014,13(2): Breast Cancer Res Treat,2015,149(3): J Control Release,2015,204:20-9 AC Chem Biol,2014,9(5): Biochim Biophys Acta,2017,1861(4): ncogene,2015,34(32): J Mol Cell Cardiol,2016,97: BMC Cancer,2015,15:239 J Mol Biol,2017, /j.jmb PLo ne,2014,9(7):e Pharmacol Res,2016,113(Pt A): ChemMedChem,2016, /cmdc PLo ne,2013,8(5):e63240 PLo ne,2016,11(2):e ChemMedChem,2016,11(11): PLo ne,2013,8(4):e60334 ensors (Basel),2016,16(3) Bioorg Med Chem,2016,24(19): Mol Med Rep,2014,10(6): PLo ne,2015,10(11):e Mol Cancer Ther,2015,14(5): ncotarget,2014,5(15): Head eck,2015,37(12): at Med,2014,20(8): Biosens Bioelectron,2015,68: Curr Protoc Chem Biol,2014,4: in Cancer Res,2015,21(5): Cell Cycle,2015,14(1): ncotarget,2015,6(3): Mol Cancer Res,2014,12(5):703-13

7 Pfizer Express-Pick Library Cat.o. L3600 ther Compound Libraries A unique collection of 4208 chemical compounds featured different parent nuclei and structural diversities respectively for high throughput screening (HT) and high content screening (HC) Innovative compounds licensed from Pfizer Drug Discovery Department Complex chemical structures and pharmacophores which probe interactions with targets, provides dramatically increased discovery speeds for new drugs ize (Pre-dissolved in DM) Epigenetics Compound Library Cat.o. L1900 A unique collection of 273 small molecule modulators with biological activity used for epigenitc research. Inhibitor Library Cat.o. L1100 A unique collection of 1928 inhibitors for high throughput screening (HT) and high content screening (HC). DM solution) tem Cell ignaling Compound Library Cat.o. L2100 A unique collection of 99 small molecule inhibitors used for stem cell regulatory and signaling pathway research. Express-Pick Library Composition tructure ame ID Formula Molecular Weight Target elective Inhibitor Library Cat.o. L3500 A unique collection of validated bioactive compounds covering over 592 targets. F H WAY C 23H 22F GPCR Compound Library Cat.o. L2200 A unique collection of 485 GPCR small molecule compound library for GPCR screening. H H WAY C 14H Anti-cancer Compound Library Cat.o. L3000 H H H F F F WAY C 19H 16F A unique collection of 1043 compounds with anti-cancer activity for high throughput screening (HT) and high content screening (HC). H H WAY C 15H Tyrosine Kinase Inhibitor Library Cat.o. L1800 A unique collection of 195 tyrosine kinase inhibitors for high throughput screening (HT) and high content screening (HC). H WAY C 20H Ion Channel Ligand Library Cat.o. L2700 WAY C 17H A unique collection of 73 ion channel ligands. Apoptosis Compound Library Cat.o. L3300 H H GI C 14H A unique collection of 123 small molecules used for apoptosis research targeting Bcl-2, Caspase, p53, TF-alpha, Mdm2, survivin, etc. H H WAY C 15H Autophagy Compound Library Cat.o. L2600 A unique collection of 156 autophagy signaling pathway ihibitors. WAY C 16H Cambridge Cancer Compound Library Cat.o. L2300 A unique collection of 250 anti-cancer compounds. Pfizer Licensed Compound Library Cat.o. L bioactive compounds are licensed by Pfizer and have been marketed or clinically proven.

ther Compound Libraries Molecular Library Global Partners PI3K/Akt Inhibitor Library Cat.o. L2800 A unique collection of 125 PI3K signaling pathway inhibitors. MAPK Inhibitor Library Cat.o. L3400 A unique collection of 65 small molecule inhibitors used for MAPK signaling research.

Anti-infection Compound Library Cat.o. L3100 A unique collection of 323 anti-infective small molecules with biological activity of antibiotics, antifungal drugs, anti-hiv, etc.

8 ther Compound Libraries Molecular Library Global Partners PI3K/Akt Inhibitor Library Cat.o. L2800 A unique collection of 125 PI3K signaling pathway inhibitors. MAPK Inhibitor Library Cat.o. L3400 A unique collection of 65 small molecule inhibitors used for MAPK signaling research. Protease Inhibitor Library Cat.o. L2500 A unique collection of 68 small molecule inhibitors used for chemical genomics, high-throughput screening (HT), and high content screening (HC). Anti-infection Compound Library Cat.o. L3100 A unique collection of 323 anti-infective small molecules with biological activity of antibiotics, antifungal drugs, anti-hiv, etc. Anti-diabetic Compound Library Cat.o. L2900 A unique collection of 29 small molecules affecting the development of diabetes. FAQ Metabolism Compound Library Cat.. L3700 A unique collection of 431 small molecule compounds used for metabolic research. Drug Repurposing Library Cat.o. L3800 A unique collection of 1729 drugs that are marketed around the world or that have passed phase 1 clinical trials for high throughput screening (HT) and high content screening (HC). inical Compound Library Cat.o. L3900 A unique collection of 466 clinical compounds for high throughput screening (HT) and high content screening (HC). euronal ignaling Compound Library Cat.o. L4000 A unique collection of 582 small molecule compounds with biological activity used for neurologic research and associated assays. Immunology/Inflammation Compound Library Cat.o. L4100 A unique collection of 270 small molecules modulators (inhibitors and activators) with biological activity used for Immunology/Inflammation research and associated assays. Express-Pick Library (Premium Version) Cat.. L5000 A unique collection of innovative chemical compounds, from the largest pharmaceutical company in the word, features numerous structurally diverse compounds and several alternate compositions, for high throughput screening (HT) and high content screening (HC). Please visit to inquire prices of other compound libraries. Q1 Q2 Q3 Q4 After screening success, are there patent issues? The compounds themselves do not have any patent issues, when we say discovered a hit generally refers to the expandation of a new indication for a drug, R&D can certainly apply for a patent, this is not a concern of elleck nor the original drug company. In fact, drug repurposing is a very hot research area, for example, Gefitinib, approved by the FDA for treatment of CLC (non-small cell lung cancer), is now involved in over 400+ clinical trials, involving lung cancer, head and neck cancer, salivary gland cancer, esophageal cancer, breast cancer, kidney cancer, ovarian cancer, colon cancer, and many other diseases. How long does it take, using elleck Libraries, to publish an article and what kind of article? According to Research Journals, it takes an average of 2 years to publish an article, while, the impact factor ranges from 3 to 39. Interested in a elleck Library, but don t have the time or energy for experiments? elleck provides free user training through lectures, technical support and other ways to help. For those without time, we can provide references to our network of technical service providers. Why do some elleck Libraries contain fewer compounds than other companies? elleck libraries do not contain any controlled products, or other unrelated products; nor do we add both salt and non-salt version in the same library. If we only consider effective molecules, elleck libraries contain more compounds and is updated every three months, the best choice.

COMPOUND LIBRARIES. Target Molecule Corp Drug Screening Expert (Inhibitors, Libraries, Natural Compounds)

COMPOUND LIBRARIES. Target Molecule Corp Drug Screening Expert (Inhibitors, Libraries, Natural Compounds) COMPOUND LIBRARIES 2016-2017 Target Molecule Corp. ---Drug Screening Expert (Inhibitors, Libraries, Natural ) www.targetmol.com About us Target Molecule Corp. (TargetMol) is a global high-tech enterprise,